72 related articles for article (PubMed ID: 77217)
41. Bromocriptine in the treatment of the premenstrual syndrome.
Andersen AN; Larsen JF
Drugs; 1979 May; 17(5):383-8. PubMed ID: 572290
[No Abstract] [Full Text] [Related]
42. THE INFLUENCE OF STILBESTROL AND TESTOSTERONE ON THE GROWTH OF PROSTATIC ADENOMA AND CARCINOMA IN TISSUE CULTURE.
WOJEWSKI A; PRZEWORSKA-KANIEWICZ D
J Urol; 1965 Jun; 93():721-4. PubMed ID: 14300280
[No Abstract] [Full Text] [Related]
43. The value of electron microscopy in diagnostic pathology. Case 4.
Rohr HP; Bartsch G
Ultrastruct Pathol; 1980; 1(1):89-95. PubMed ID: 6165121
[No Abstract] [Full Text] [Related]
44. Hormonal responsiveness of prostatic carcinoma. In vitro technique for prediction.
Mobbs BG; Johnson IE; Connolly JG
Urology; 1974 Jan; 3(1):105-6. PubMed ID: 4130384
[No Abstract] [Full Text] [Related]
45. Prolactin.
N Engl J Med; 1978 May; 298(20):1145-6. PubMed ID: 643037
[No Abstract] [Full Text] [Related]
46. [Prostate adenoma and carcinoma].
HERBST R
Prakt Arzt; 1952 Sep; 6(64):499-509. PubMed ID: 13026681
[No Abstract] [Full Text] [Related]
47. Myopia during bromocriptine treatment.
Manor RS; Dickerman Z; Llaron Z
Lancet; 1981 Jan; 1(8211):102. PubMed ID: 6109106
[No Abstract] [Full Text] [Related]
48. [Therapy of prostatic adenoma by gestagenic agents].
Malatinský E
Bratisl Lek Listy; 1973 Jul; 60(1):106-8. PubMed ID: 4127844
[No Abstract] [Full Text] [Related]
49. [Conservative therapy of prostatic adenomas with sitosterin from Hypoxis roperi. Results of a clinical study].
Barsom S
ZFA (Stuttgart); 1978 Jul; 54(20):1067-9. PubMed ID: 676445
[No Abstract] [Full Text] [Related]
50. The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.
Jeromin L
Int Urol Nephrol; 1982; 14(1):51-6. PubMed ID: 6889585
[TBL] [Abstract][Full Text] [Related]
51. Alterations of peripheral testosterone matabolism after induced hypoprolactinemia in patients with prostatic carcinoma.
Jacobi GH; Altwein JE; Hohenfellner R
Klin Wochenschr; 1979 Jan; 57(1):49-51. PubMed ID: 759717
[TBL] [Abstract][Full Text] [Related]
52. [Treatment of prostatic carcinoma with phostrolin and bromocriptine while monitoring serum concentrations of testosterone and prolactin].
Jeromin L
Pol Tyg Lek; 1980 Mar; 35(10):359-62. PubMed ID: 7367321
[No Abstract] [Full Text] [Related]
53. [Prolactin and cancer of the prostate. IV. Prolactin inhibition in the treatment of prostatic cancer].
Maganto Pavón E; Mayayo Dehesa T; Mateos Torres JA; Boronat Tormo F; Verdú Tartajo F; de Blas Gómez V
Arch Esp Urol; 1982; 35(5):312-25. PubMed ID: 6758710
[No Abstract] [Full Text] [Related]
54. [Relation of prolactin with nodular hyperplasia and carcinoma of the prostate].
Romero L; Muñoz C; López A; Vilches J
Actas Urol Esp; 1991; 15(6):503-9. PubMed ID: 1724345
[TBL] [Abstract][Full Text] [Related]
55. [Bromocriptine, a new therapeutic principle in prostatic adenoma and carcinoma. Basis, possibilities, limits].
Jacobi GH; Altwein JE
Dtsch Med Wochenschr; 1978 May; 103(19):827-33. PubMed ID: 77217
[No Abstract] [Full Text] [Related]
56. [Bromocryptin, a new therapeutic principle in adenoma and carcinoma of the prostate. Presuppositions, possibilities and limitations].
Jacobi GH; Altwein JE
Minerva Urol; 1980; 32(3):167-73. PubMed ID: 6159524
[No Abstract] [Full Text] [Related]
57. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate.
Taşar C; Akdaş A; Kirkali Z
Int Urol Nephrol; 1986; 18(1):71-4. PubMed ID: 2424860
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
